证券代码：300434 证券简称：金石亚药 公告编号：2026-004 四川金石亚洲医药股份有限公司 关于子公司参与国家组织集采药品协议期满 本次接续采购为国家组织集采药品协议期满品种接续采购，约定采购量以医 药机构填报各企业采购品种需求量为基数，按照中选价格梯度确定带量比例。本 次集采中选结果将于 2026 年 3 月实施，中选药品的采购周期自中选结果实际执 行日起至 2028 年 12 月 31 日。上述产品中选采购量及中选价格均以接续采购办 公室发布的最终数据为准。若后续签订采购协议并实施，将有利于提高公司产品 的市场占有率，提升公司品牌影响力，对公司未来发展具有积极的影响。 三、风险提示 公司中选产品的采购合同签订等后续事项以及带量采购后市场销售执行情 况尚具有不确定性。敬请广大投资者谨慎决策，注意投资风险。 特此公告。 品种接续采购中选的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 近日，四川金石亚洲医药股份有限公司（以下简称"公司"）全资一级子公 司海南亚洲制药股份有限公司（以下简称"亚洲制药"）参加了国家组织集采药 品协议期满品种接续采购 ...

Group 1 - The company, Jinshi Yaya (300434.SZ), is actively promoting research and exploration of vacuum coating technology in new fields [1]

Group 1 - The company, Jinshi Yaya (300434.SZ), is actively promoting research and exploration of vacuum coating technology in new fields [1]

Group 1 - The company Jinshiyao announced that board member Zheng Zhiyong and shareholder Jiang Erchen's share reduction plan has reached its deadline [1] - Zheng Zhiyong plans to reduce his holdings by selling 240,000 shares at an average price of 10.9 yuan per share, which represents 0.06% of the total share capital, between December 26, 2025, and January 22, 2026 [1] - Jiang Erchen intends to sell 70,000 shares at an average price of 13.18 yuan per share, accounting for 0.02% of the total share capital, on November 26, 2025 [1] Group 2 - After the share reductions, Zheng Zhiyong will hold 3.4653 million shares, representing 0.86% of the total share capital [1] - Jiang Erchen will hold 157,000 shares, which is 0.04% of the total share capital after the reduction [1]

Group 1 - The company announced that board member Zheng Zhiyong and shareholder Jiang Erchen have completed their share reduction plans [1] - Zheng Zhiyong plans to reduce 240,000 shares at an average price of 10.9 yuan per share, accounting for 0.06% of the total share capital, between December 26, 2025, and January 22, 2026 [1] - Jiang Erchen intends to reduce 70,000 shares at an average price of 13.18 yuan per share, representing 0.02% of the total share capital, on November 26, 2025 [1] Group 2 - After the share reductions, Zheng Zhiyong will hold 3.4653 million shares, which is 0.86% of the total share capital [1] - Jiang Erchen will hold 157,000 shares, accounting for 0.04% of the total share capital after the reduction [1]

证券代码：300434 证券简称：金石亚药 公告编号：2026-003 四川金石亚洲医药股份有限公司 关于董事、股东减持计划期限届满的公告 公司董事郑志勇先生、股东姜二晨先生保证向本公司提供的信息内容真 实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 本公司及董事会全体成员保证公告内容与信息披露义务人提供的信息 一致。 四川金石亚洲医药股份有限公司（以下简称"公司"）2025年10月29日披露 了《关于董事、股东减持股份的预披露公告》（公告编号：2025-042）：公司董 事郑志勇先生，持有本公司股份3,705,304股（占本公司总股本比例0.92%）计划 自上述公告披露之日起十五个交易日后的三个月内以集中竞价交易或大宗交易 方式，减持所持有的本公司股份不超过926,326股（占本公司总股本比例0.23%）； 公司股东姜二晨先生，持有本公司股份227,000股（占本公司总股本比例0.06%） 计划自上述公告披露之日起十五个交易日后的三个月内以集中竞价交易或大宗 交易方式，减持所持有的本公司股份不超过227,000股（占本公司总股本比例 0.06%）。 截至本公告披露日，上述减持计划期限已届满，现将减持计 ...

Group 1 - The company, Jinshi Yao, responded to investor inquiries on February 5, indicating that details regarding its research projects can be found in the company's regular reports [2]

Group 1 - The company Jinshi Yao (300434) disclosed its "2025 Annual Performance Forecast" on January 29, 2026 [1]

Core Viewpoint - Jinshi Yao (300434.SZ) expects a net profit attributable to shareholders of 118.91 million to 154.45 million yuan for 2025, representing a year-on-year growth of 29.58% to 68.31% [1] Group 1: Financial Performance - The company anticipates a net profit of 97.90 million to 133.44 million yuan after deducting non-recurring gains and losses, indicating a year-on-year growth of 18.96% to 62.15% [1] - The overall business remains stable, with profit growth supported by effective budget optimization and cost control measures [1] Group 2: Business Development - The new materials and machinery sectors have benefited from successful commercialization of prior R&D results, leading to improved sales gross margin and gross profit [1] - Increased demand for cold medicine has positively impacted sales of anti-influenza virus products, further enhancing the company's profitability [1] Group 3: Non-recurring Gains - The estimated impact of non-recurring gains and losses on net profit is approximately 21.01 million yuan [1]

Group 1: Company Performance and Revenue - Luzhou Laojiao's overseas revenue is approximately 186 million yuan, accounting for 0.60% of total revenue [1][14] - Sichuan Shuangma focuses on biomedicine and has established a portfolio of innovative drugs in various disease areas, with a strong global supply capability for peptide raw materials [2][15] - Sichuan Shuangma's peptide products are exported to countries including the USA, Brazil, India, and Spain, with a significant presence in the chronic disease treatment market [2][15] Group 2: Product Applications and Market Expansion - Sichuan Shuangma produces over a hundred types of beauty peptides, collaborating with leading global cosmetic brands to enhance product innovation [3][16] - Zhongmi Holdings has applied its high-speed mechanical seals in commercial aerospace, although this segment's revenue is relatively low compared to its traditional petrochemical market [4][17] - Zhongmi Holdings is monitoring the demand for sealing products in the large aircraft sector but has not identified significant market needs yet [5][18] Group 3: Technological Development and Future Prospects - Jinshi Yaya's vacuum coating technology is not currently applied in space photovoltaic equipment but the company is exploring potential collaborations in other fields [6][19] - Houpu Co. has experience in distributed energy projects in both natural gas and hydrogen applications [7][20] - Zhimin Da is developing a high-radiation-resistant computing platform for space applications, although this technology is still in the research phase [8][21] Group 4: Market Strategy and Competitive Position - Sichuan Jiuzhou has successfully entered the overseas market with its Wi-Fi routers, while focusing on domestic sales for its camera products [12][25] - Jiuzhou's subsidiary is actively pursuing opportunities in the low-altitude economy, with significant progress in technology and product development [12][25] - Kexin Mechanical and Electrical is concentrating on high-end process equipment in energy and chemical sectors, while exploring new growth points in intelligent manufacturing [10][24]